GLP-1 Medications and Chronic Pain: What the Evidence Actually Shows

More of our patients now arrive already taking a GLP-1 medication — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), or liraglutide. And more of them are asking a fair question: could this drug be helping my pain? Some notice their knees feel better within months of starting. Here is what the research actually shows, where it is strong, where it is still early, and what it means if you are scheduled for a procedure.

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It tells the pancreas to release insulin, slows how quickly the stomach empties, and signals the brain that you are full. GLP-1 medications mimic that hormone, with effects that last a day or a full week per dose.

They were developed for type 2 diabetes, then approved for weight management. In a January 2026 review in Nature Medicine, Dr. Daniel Drucker — one of the scientists whose work laid the foundation for this drug class — describes how their uses have spread to heart disease, kidney disease, fatty liver disease, sleep apnea, and osteoarthritis, while noting that real questions about long-term use remain open.[1]

The best human data on GLP-1 drugs and pain comes from a single large, well-designed trial. STEP 9, published in the New England Journal of Medicine, enrolled 407 adults who had obesity and moderate knee osteoarthritis with at least moderate pain.[2] For 68 weeks, participants received either weekly semaglutide 2.4 mg or a placebo injection, and everyone received counseling on diet and physical activity.

The results:

• Weight: the semaglutide group lost about 13.7% of body weight, versus about 3.2% on placebo.
• Pain: on a 100-point knee pain scale, scores fell by roughly 42 points with semaglutide versus about 28 points with placebo.
• Function: physical function improved more in the semaglutide group.
• Tolerability: about 7% stopped the drug because of side effects, mostly gastrointestinal, compared with 3% on placebo.

Two cautions matter. Every participant had obesity, so we do not know whether the same benefit applies to people at a healthy weight. And the trial was not designed to tell us whether the pain relief came from weight loss itself or from a direct effect of the drug on the joint. The study was funded by the manufacturer.

There are two plausible routes, and they are not mutually exclusive.

Indirect effects. Less body weight means less load on weight-bearing joints. Better blood sugar matters for nerve health. Lower whole-body inflammation can make painful conditions less reactive. And people who hurt less tend to move more, which helps on its own.

Possible direct effects. In laboratory and animal studies, GLP-1 receptors have been found on immune cells in the spinal cord called microglia. Activating them appears to trigger the release of anti-inflammatory signals and the body's own endorphins, calming pain in animal models of inflammatory, nerve, and migraine pain.[3][4] That is a genuinely interesting finding — but it has not yet been shown to produce meaningful pain relief at the doses people actually take.

• Diabetic neuropathy: small studies have shown improvements in nerve structure and nerve-conduction measures, but strong evidence that patients feel less pain is still missing.[3]
• Headache: most of the migraine data comes from animal studies. Weight loss on GLP-1 drugs has shown benefit in idiopathic intracranial hypertension, a specific pressure-related headache disorder.[3]
• Fibromyalgia: a large records-based study of roughly 96,000 matched patients found that those taking GLP-1 drugs had fewer opioid prescriptions and fewer pain-related diagnoses over five years.[5] That is encouraging, but a study of this kind cannot prove the drug caused the difference.
• Irritable bowel syndrome: an experimental GLP-1–based drug relieved acute abdominal pain episodes in trials — yet the long-acting GLP-1 drugs in common use can also worsen nausea, bloating, and abdominal discomfort in some people.[3]

The most current summary for pain physicians comes from a team of anesthesiology and pain medicine specialists whose review, indexed in the National Institutes of Health's PubMed Central database, covered the literature through May 2026.[3] Their conclusion was direct: GLP-1 drugs are "not established analgesics." Current evidence does not support prescribing them purely for pain in someone who lacks an approved reason to take them.

Where they do seem to help, the benefit most likely runs through weight loss, metabolic improvement, and better function — which is still a real benefit, just a different one than a pain pill.

Because these medications slow stomach emptying, food can remain in the stomach even after a standard overnight fast. Under sedation or anesthesia, that raises the risk of stomach contents entering the lungs. For an injection done with local anesthetic alone, this usually has little practical impact. When sedation is planned, it matters.[3]

If you take any GLP-1 medication:

• Tell us the drug name, your dose, and the day of your last injection when you schedule.
• Do not stop or skip doses on your own. Guidance on whether and when to hold these drugs has changed over the past few years, and the right plan depends on your dose, your procedure, and why you take the medication.
• Let us know about ongoing nausea, vomiting, or bloating, which can signal slowed digestion.

Our practice is built on evidence-based, non-opioid care, so we follow this research closely. A GLP-1 drug is not a substitute for finding out why something hurts. But for a patient with obesity-related knee arthritis, meaningful weight loss — including with a GLP-1 medication prescribed for an approved indication — can be one part of a whole-person plan alongside targeted procedures, non-opioid medications, and physical rehabilitation. Pairing weight loss with strength work matters, because rapid weight loss can take some muscle with it, and strong muscles protect painful joints.

Dr. Scott personally sees every patient at every visit. If you are taking a GLP-1 medication, or wondering how one might fit into your pain care, bring it up at your appointment and we will look at the whole picture together.

This article is for general education and is not a substitute for individual medical advice. Do not start, stop, or change any medication without talking with your physician.

1. Drucker DJ. The expanding landscape of GLP-1 medicines. Nature Medicine. 2026;32:47–57. https://doi.org/10.1038/s41591-025-04124-5
2. Bliddal H, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. New England Journal of Medicine. 2024. https://doi.org/10.1056/NEJMoa2403664
3. Hyung SW, et al. Glucagon-like peptide-1 receptor agonists and chronic pain: preclinical antinociceptive mechanisms, indirect metabolic–functional effects, and clinical considerations — a narrative review. Journal of Clinical Medicine. 2026;15(15):5932. National Institutes of Health, PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC13466897/
4. Advances in GLP-1 receptor agonists for pain treatment and their future potential. Journal of Headache and Pain. 2025;26(1):46. National Institutes of Health, PubMed: https://pubmed.ncbi.nlm.nih.gov/40016636/
5. Exploring the effects of GLP-1 receptor agonists in fibromyalgia: a propensity-matched real-world cohort using the TriNetX research platform. Annals of the Rheumatic Diseases. 2025;84:232. https://doi.org/10.1016/j.ard.2025.05.291